

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
15 September 2022 (15.09.2022)



(10) International Publication Number
WO 2022/192533 A1

(51) International Patent Classification:

A61P 5/00 (2006.01) C07D 401/14 (2006.01)
A61P 11/00 (2006.01) C07D 413/14 (2006.01)
A61P 17/00 (2006.01) C07D 417/14 (2006.01)
A61P 19/00 (2006.01) A61K 31/553 (2006.01)
A61P 35/00 (2006.01) A61K 31/55 (2006.01)
A61P 37/00 (2006.01)

(21) International Application Number:

PCT/US2022/019744

(22) International Filing Date:

10 March 2022 (10.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/159,970 11 March 2021 (11.03.2021) US

(71) Applicant: RIGEL PHARMACEUTICALS, INC.

[US/US]; 1180 Veterans Boulevard, South San Francisco,
California 94080 (US).

(72) Inventors: BHAMIDIPATI, Somasekhar; c/o RIGEL

PHARMACEUTICALS, INC., 1180 Veterans Boulevard,
South San Francisco, California 94080 (US). DEFREES,
Kyle; c/o RIGEL PHARMACEUTICALS, INC., 1180 Veterans
Boulevard, South San Francisco, California 94080
(US). SHAW, Simon; c/o RIGEL PHARMACEUTICALS,
INC., 1180 Veterans Boulevard, South San Francisco,
California 94080 (US). TAYLOR, Vanessa; c/o RIGEL
PHARMACEUTICALS, INC., 1180 Veterans Boulevard,
South San Francisco, California 94080 (US).

(74) Agent: LENTZ, Nelsen L. et al.; ELI LILLY AND COM-

PANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288
(US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,

RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: HETEROCYCLIC RIP1 KINASE INHIBITORS



Formula I

(57) Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds of formula (I), as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP 1-associated disease or condition.



WO 2022/192533 A1